These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 25252180)

  • 21. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
    De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
    J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
    De Giorgi U; Scarpi E; Sacco C; Aieta M; Lo Re G; Sava T; Masini C; De Vincenzo F; Baldazzi V; Camerini A; Fornarini G; Burattini L; Rosti G; Ferrari V; Moscetti L; Chiuri VE; Luzi Fedeli S; Amadori D; Basso U
    Clin Genitourin Cancer; 2014 Jun; 12(3):182-9. PubMed ID: 24369790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
    Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
    George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
    Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic significance of sunitinib-induced "off-target" side effects].
    Maráz A; Cserháti A; Uhercsák G; Szilágyi E; Varga Z; Kahán Z
    Magy Onkol; 2014 Sep; 58(3):167-72. PubMed ID: 25260080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
    Czarnecka AM; Sobczuk P; Korniluk J; Spychalska M; Bogusz K; Owczarek A; Brodziak A; Labochka D; Moszczuk B; Szczylik C
    Future Oncol; 2017 Jan; 13(1):31-49. PubMed ID: 27599260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.
    Miyake H; Miyazaki A; Harada K; Fujisawa M
    Med Oncol; 2014 Jun; 31(6):978. PubMed ID: 24793747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
    Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
    Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Bozkurt O; Karaca H; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    J Chemother; 2016 Jun; 28(3):230-4. PubMed ID: 25948423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.
    Schnadig ID; Hutson TE; Chung H; Dhanda R; Halm M; Forsyth M; Vogelzang NJ
    Clin Genitourin Cancer; 2014 Dec; 12(6):413-21. PubMed ID: 25163396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH; Park I; Lee JL
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.